Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …

Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …

Background There is a paucity of data on the natural trajectory of outcomes in survivors of
COVID-19 beyond 2 years after symptom onset, and no evidence exists on the effect of re …

BACKGROUND When considering whether a patient is fit for surgery, a comprehensive
patient assessment represents the first step for an anaesthetist to evaluate the risks …

The long-term physiological consequences of respiratory viral infections, particularly in the
aftermath of the COVID-19 pandemic—termed post-acute sequelae of SARS-CoV-2 (PASC) …

Surviving critical illness does not always equate to recovery, with its aftermath frequently
complicated by post-intensive care syndrome (PICS). This syndrome consists of a collection …

Pirfenidone and Nintedanib are specific drugs used against idiopathic pulmonary fibrosis
(IPF) that showed efficacy in non-IPF fibrosing interstitial lung diseases (ILD). Both drugs …

As COVID-19 continues, an increasing number of patients develop long COVID symptoms
varying in severity that last for weeks, months, or longer. Symptoms commonly include …

Rationale: Incidental parenchymal abnormalities detected on chest computed tomography
scans are termed interstitial lung abnormalities (ILAs). ILAs may represent early interstitial …

Background The scale of COVID-19 and its well documented long-term sequelae support a
need to understand long-term outcomes including frailty. Methods This prospective cohort …